Biomerieux Shares Drop 8% Over the Week, Hindered by Downward Momentum
Biomerieux experienced a challenging week, with a decline of 8%, which starkly contrasts with the relative stability of major indices. The stock closed at 104.60 euros, further sinking into the red and widening the gap with its already negative annual performance. This trend reveals persistent selling pressure on the medical diagnostics group, far from the bullish orientation of the Parisian market.
Biomerieux ended the week down by 8%, with a closing price set at 104.60 euros. This performance starkly contrasts with its environment: the CAC 40 gained 0.19% over the same period, while the SBF 120 advanced by 0.13%. The discrepancy is thus evident. Throughout 2025 to date, the stock has suffered a decline of 4.82%, indicative of a bearish trend that has been established for several months. The stock now trades well below its moving averages: the 50-day average stands at 108.18 euros, while the 200-day average is at 115.40 euros, creating a deteriorated chart configuration. Analysts have set a three-month price target of 123.74 euros, suggesting a potential upside of 17.29%, even though this hope is not enough to stem the current sales. The estimated yield for 2026 stands at 1.03%, with a dividend expected to be 1.16 euros per share.
Technical Analysis Insights
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Technical analysis offers no immediate signs of stabilization. The Relative Strength Index (RSI) stands at 35, indicating a marked selling dynamic, while the MACD shows a line at -0.29, confirming the weakness of momentum. The stock is now fluctuating between its support levels at 104.20 euros and resistance at 114.80 euros, in a narrow range that limits volatility, measured at 6.23% over a month. The Bollinger Bands, positioned between 105.05 and 114.89 euros, enclose the price near their lower limit, reflecting bearish pressure. The beta ratio of -0.18 suggests a reverse sensitivity to the market, an atypical trait that may reflect specific sector dynamics of the group or a specific portfolio composition. This technical setup calls for increased vigilance, especially if the stock were to test its current supports.
Dans un contexte de faible activité épidémiologique, nous continuons à faire croître notre base installée, en particulier pour BIOFIRE® et SPOTFIRE®, et à améliorer la rentabilité dans le cadre du plan GO•28.
Ventes consolidées de 2 992 millions d'euros sur 9 mois (+4,2 % publié, +7,3 % organique). Forte croissance des panels non-respiratoires et de SPOTFIRE (croissance organique 114 %), ralentissement en Chine et moindre épidémiologie respiratoire. Révision de la guidance organique 2025 à +5,5 % / +6,5 %; ROCC attendu +12 % / +18 %. Effet de change négatif -85 millions d'euros sur les ventes 9 mois et ~-30 millions d'euros attendu sur le CEBIT annuel.
Risks mentioned
faible activité épidémiologique impactant les ventes de panels respiratoires
recul significatif des ventes en Chine
risque de change défavorable (impact -85 millions d'euros sur 9 mois, ~-30 millions d'euros sur CEBIT attendu)
risques liés aux économies en hyperinflation (Argentine, Turquie)
Opportunities identified
forte dynamique de SPOTFIRE (base installée >5 500, +160 % sur 12 mois)
croissance des panels non-respiratoires BIOFIRE
développements de nouveaux produits (GENE-UP® PRO HRM) et lancements soutenant les applications industrielles
croissance robuste des Applications Industrielles, notamment Contrôle Qualité Pharmaceutique (+15 %)
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
